PDE

PDE

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond.When phosphodiesterase is mentioned, it usually refers to cyclic nucleotide phosphodiesterases, which are discussed below and have significant clinical implications. There are numerous other families of phosphodiesterases, however, including the phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, in addition to a large number of less well-studied small-molecule phosphodiesterases.A group of enzymes known as cyclic nucleotide phosphodiesterases breaks down the phosphodiester bond in the second messenger molecules cAMP and cGMP. Within subcellular domains, they control the cyclic nucleotide signaling's amplitude, duration, and localization. Therefore, PDEs play a crucial role in controlling the signal transduction process that these second messenger molecules mediate.

PDE related products

Structure Cat No. Product Name CAS No. Product Description
V0786 Icariin (Ieariline) 489-32-7 Icariin (also called Ieariline), a naturally occuring flavonol glycoside found in Epimedium (aChinese medicinal herb), is a potentcGMP-specific Phosphodiesterase PDE5 inhibitorwith important biological activity.
V0796 Irsogladine 57381-26-7 Irsogladine (MN1695; MN 1695; Gaslon; MN-1695; Dicloguamine),a mucosal protective drug, is a novel and potent PDE4 inhibitor and muscarinic acetylcholine receptor binder with anti-ulceric activity.
V51700 LASSBio-1632 LASSBio-1632 is a lead compound with anti-asthmatic activity that selectively inhibits PDE4A and PDE4D isoenzymes, blocking airway hyperresponsiveness and TNF-α production in lung tissue.
V14147 Lotamilast (RVT501; E6005) 947620-48-6 Lotamilast (formerly RVT-501; E-6005) is a novel, potent and selective inhibitor of phosphodiesterase 4 (PDE-4,IC50= 2.8 nM) with the potential to be used for the treatment of AD/atopic dermatitis.
V0799 Luteolin 491-70-3 Luteolin (also known as Digitoflavone; Salifazide; BRN0292084;RN 0292084; Luteolol)is a naturally occuring flavonoidisolated from plants such asTerminalia chebula, which is a non-selective phisphodiesterase PDE inhibitor for PDE1-5 with Ki values of 15.0 μM, 6.4 μM, 13.9 μM, 11.1 μM and 9.5 μM, respectively.
V0792 Mardepodect (PF-2545920; MP-10) 898562-94-2 Mardepodect (formerly known as PF-2545920, PF2545920, MP10; MP-10) is a novel, potent and selective PDE10A (phosphodiesterase) inhibitor with antipsychotic activity.
V2648 Mardepodect HCl (PF-2545920 HCl) 2070014-78-5 Mardepodect HCl, the hydrochloric acid salt of PF-2545920 (Also known as Mardepodect,MP-10), is a novel, potent and selective PDE10A (phosphodiesterase) inhibitor with IC50 of 0.37 nM, andwith >1000-fold selectivity over the PDE.
V0795 Milrinone (Win47203; Primacor) 78415-72-2 Milrinone (formerly known as Win-47203;Win 47203; trade name Primacor) is a potent and selective phosphodiesterase 3 (PDE3) inhibitor that is used as apulmonary vasodilator to increase the hearts contractility.
V51037 MK-8189 1424371-93-6 MK-8189 is a potent and specific PDE10A with a Ki of 29 pM.
V3499 Pentoxifylline 6493-05-6 Pentoxifylline (also known as oxpentifylline, theobromine, dimethyloxohexylxanthine, EHT 0202, BL 191, BL-191; PTX, pentoxifilina, Trental), a xanthine derivative, is a nonselective PDE inhibitor used as a drug to treat muscle pain in people with peripheral artery disease.
V3378 PF-8380 1144035-53-9 PF-8380 is a novel, potent andspecificautotaxin (ATX)inhibitor with anIC50of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.
V0782 Pimobendan 74150-27-9 Pimobendan (UD-CG115; UDCG115;Trade names Vetmedin, Acardi), a veterinary medication approvedto treat CHF-congestive heart failure in dogs, is a potent and selective inhibitor ofphosphodiesterasePDE3 with positive inotropic and vasodilator effects.
V13927 RO2959 HCl 1219927-22-6 RO2959 is a novel, potent and highly selective CRAC current inhibitor (IC50 of 402 nM), also a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM.
V0777 Roflumilast (BY217; B 9302107; BYK-20869; Daxas; Daliresp) 162401-32-3 Roflumilast (BY-217; APTA-2217; B 9302-107; BYK20869; Daxas; Daliresp) is a novel, highly potent,selective, andlong-acting inhibitor of phosphodiesterase 4/PDE4 with potential anti-inflammatory activity.
V0788 Rolipram (ME 3167; ZK 62711; SB 95952) 61413-54-5 Rolipram (formerly called ME-3167; ZK-62711; SB95952;the racemic mixture of R- and S-rolipram)is a novel, potent and selective phosphodiesterase PDE4inhibitor with potential anti-inflammatory and anti-depressant activity.
V0787 S- (+)-Rolipram (ME-3167; SB95952; ZK-62711) 85416-73-5 S-(+)-Rolipram, theS-isomer of rolipram (ME3167;SB-95952; ZK62711), isa potent phosphodiesterase PDE4-inhibitor with potent anti-inflammatory and anti-depressant activity.
V0778 Sildenafil Citrate (UK-92480 citrate; Revatio) 171599-83-0 Sildenafil Citrate (formerly also known as UK-92480 citrate; Trade names Revatio; among others), the citrate form of Sildenafil, is a potentandselective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) withIC50of 5.22 nM.
V37606 Sildenafil Mesylate 1308285-21-3 Sildenafil Mesylate (formerly UK-92480; UK92480;Revatio), the mesylate salt form of Sildenafil, is deemed asthe best treatment for erectile dysfunction.
V0780 Tadalafil (IC 351; Cialis) 171596-29-5 Tadalafil (formerly known as IC351; IC-351;trade name Cialis) is a potent, orally bioavailable, reversible and competitive small-molecule inhibitor of PDE-5 (phosphodiesterase 5) with the potential to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension.
V2623 TAK-063 (Balipodect) 1238697-26-1 Balipodect (formerly also known as TAK-063) is a novel,highly potent, orally bioavailable and selective phosphodiesterase 10A (PDE10A) inhibitor with potential usefulness inthe treatment of schizophrenia.
Contact Us Back to top